Cargando…

CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment

Germline CTLA-4 deficiency causes severe autoimmune diseases characterized by dysregulation of Foxp3(+) Tregs, hyper-activation of effector memory T cells, and variable forms autoimmune cytopenia including gradual loss of B cells. Cancer patients with severe immune-related adverse events (irAE) afte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muthana, Musleh M., Du, Xuexiang, Liu, Mingyue, Wang, Xu, Wu, Wei, Ai, Chunxia, Su, Lishan, Zheng, Pan, Liu, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002750/ https://www.ncbi.nlm.nih.gov/pubmed/36909522 http://dx.doi.org/10.1101/2023.03.01.530608

Ejemplares similares

Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
por: Tang, Fei, et al.
Publicado: (2018)

Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy
por: Zhang, Yan, et al.
Publicado: (2019)

Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice
por: Du, Xuexiang, et al.
Publicado: (2018)

S-15 in combination of Akt inhibitor promotes the expansion of CD45RA(−)CCR7(+) tumor infiltrating lymphocytes with high cytotoxic potential and downregulating PD-1(+)Tim-3(+) cells as well as regulatory T cells
por: Xu, Benling, et al.
Publicado: (2019)

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
por: Du, Xuexiang, et al.
Publicado: (2018)

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
por: Peggs, Karl S., et al.
Publicado: (2009)

Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies
por: Zhang, Peng, et al.
Publicado: (2020)

Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibody
por: Ciszak, Lidia, et al.
Publicado: (2015)

CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
por: Sobhani, Navid, et al.
Publicado: (2021)

CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect
por: Liu, Mingyue, et al.
Publicado: (2022)

Lymphocyte transformation induced by autologous cells. VIII. Impaired autologous mixed lymphocyte reactivity in patients with acute infectious mononucleosis
Publicado: (1979)

Role of CTLA4 in the Proliferation and Survival of Chronic Lymphocytic Leukemia
por: Mittal, Amit K., et al.
Publicado: (2013)

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
por: Zhang, Hao, et al.
Publicado: (2021)

Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes
Publicado: (1992)

CTLA-4-mediated posttranslational modifications direct cytotoxic T-lymphocyte differentiation
por: Lingel, Holger, et al.
Publicado: (2017)

Complement activated granulocytes can cause autologous tissue destruction in man
por: Löhde, E., et al.
Publicado: (1992)

DESTRUCTION OF EPIDERMAL CELLS IN VITRO BY AUTOLOGOUS SERUM FROM NORMAL ANIMALS
por: Terasaki, Paul I., et al.
Publicado: (1962)

Lymphocyte transformation induced by autologous cells. IV. Human T- lymphocyte proliferation induced by autologous or allogeneic non-T lymphocytes
Publicado: (1976)

Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study
por: Thonhoff, Jason R., et al.
Publicado: (2018)

LYMPHOCYTE PROLIFERATION IN VITRO INDUCED BY HAPTEN AUTOLOGOUS PROTEIN CONJUGATES : I. A STUDY ON THE CLASS OF LYMPHOCYTES RESPONDING IN VITRO AND ON THE NATURE AND SPECIFICITY OF THEIR RECEPTORS
por: Rubin, Bent, et al.
Publicado: (1974)

Impact of CTLA-4 checkpoint antibodies on ligand binding and Transendocytosis
por: Williams, Cayman, et al.
Publicado: (2022)

Developing and characterizing a single-domain antibody (nanobody) against human cytotoxic T-lymphocyte-associated protein 4 (hCTLA-4)
por: Sotoudeh, Nazli, et al.
Publicado: (2021)

Structure of CTLA-4 complexed with a pH-sensitive cancer immunotherapeutic antibody
por: Gao, Han, et al.
Publicado: (2020)

Cooperative Roles of CTLA-4 and Regulatory T Cells in Tolerance to an Islet Cell Antigen
por: Eggena, Mark P., et al.
Publicado: (2004)

CD4(+) regulatory T cells require CTLA-4 for the maintenance of systemic tolerance
por: Friedline, Randall H., et al.
Publicado: (2009)

CD4(+) regulatory T cells require CTLA-4 for the maintenance of systemic tolerance
por: Friedline, Randall H., et al.
Publicado: (2009)

Imaging regulatory T cell dynamics and suppression of T cell priming mediated by CTLA4
por: Matheu, Melanie P., et al.
Publicado: (2015)

Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity
por: Paterson, Alison M., et al.
Publicado: (2015)

TGFβ2 Induces the Soluble Isoform of CTLA-4 – Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma
por: Khanolkar, Rahul C., et al.
Publicado: (2022)

Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Regulates the Unfolding of Autoimmune Diabetes
por: Lühder, Fred, et al.
Publicado: (1998)

Relationship Between the Expression of PD-1 and CTLA-4 on T Lymphocytes and the Severity and Prognosis of Sepsis
por: Wang, Lang, et al.
Publicado: (2023)

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
por: Ascierto, Paolo A, et al.
Publicado: (2011)

Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
por: Karimi, Amirali, et al.
Publicado: (2021)

Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy
por: Zhang, Jingyu, et al.
Publicado: (2017)

Autologous stimulation of human lymphocyte subpopulation
Publicado: (1975)

A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells
por: Weber, Tobias, et al.
Publicado: (2015)

Protein Kinase C-η Controls CTLA-4-Mediated Regulatory T Cell Function
por: Kong, Kok-Fai, et al.
Publicado: (2014)

TGF-β2 mediated secretion of sCTLA-4 from regulatory T cells
por: Khanolkar, R, et al.
Publicado: (2015)

PD-1 and CTLA-4 exert additive control of effector regulatory T cells at homeostasis
por: Pereira, Joseph A., et al.
Publicado: (2023)

Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade
por: Lotem, Michal, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_k12rdcc51n7qbe05jp2sjri8en